Recommendations for the management and treatment of dyslipidemia: Report of the working group on hypercholesterolemia and other dyslipidemias

CMAJ. Canadian Medical Association Journal

Volumn 162, Issue 10, 2000, Pages 1441-1447

  Fodor, J George ^a,d   Frohlich, Jiri J ^b   Genest, Jacques J G ^c   McPherson, P Ruth ^d  

^a Tunney's Pasture   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ALCOHOL CONSUMPTION; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL PROTOCOL; CORONARY ARTERY DISEASE; CORONARY RISK; DIET THERAPY; DYSLIPIDEMIA; EXERCISE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; REVIEW; RISK ASSESSMENT; SCREENING TEST; TOBACCO; WEIGHT REDUCTION;

EID: 0034674011     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. 1. Heart and Stroke Foundation of Canada. The changing face of bean disease and stroke in Canada 2000. Ottawa: Laboratory Centre for Disease Control, Health Canada, Statistics Canada, Canadian Institute for Health Information, Canadian Cardiovascular Society, Canadian Stroke Society, Heart and Stroke Foundation of Canada; 1999.
2. 2. Anitschkow N. Über die Veranderungen der Kaninchenaorta bei experimenteller Cholesterinsteatose. Beitr Pathol Anat 1913;56:379-404.
3. 3. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
4. 4. Brensike J, Levy R, Kelsey S, Passamani E, Richardson J, Loh I, et al. Effects of therapy with cholestyramine on progression of coronary atherosclerosis: results of the NHLBI Type II coronary intervention study. Circulation 1984; 69:124-31.
5. 5. Canadian Consensus Conference on Cholesterol. Final report, Canadian Consensus Conference on the prevention of heart and vascular disease by altering serum cholesterol and serum lipoprotein factors. CMAJ 1988;139:111-63.
6. 6. Brown B, Albers J, Fisher L, Schaefer S, Lin J, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in patients with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
7. 7. Kane J, Malloy M, Ports T, Phillips N, Diehl J, Havel R. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12.
8. 8. Buchwald H, Varco R, Matts J, Long J, Fitch L, Campbell G. Effects of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypereholesterolemia: report on the Program on Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-55.
9. 9. Ornish D, Brown S, Scherwitz L, Billings J, Armstrong W, Ports T, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990;336:129-33.
10. 10. Watts G, Lewis B, Brunt J, Lewis E, Coltart D, Smith L, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.
11. 11. Cashin-Hemphill L, Mach W, Pogoda M, Sanmarco M, Azen S, Blankehorn D. Beneficial effects of colestipol-niacin on coronary atherosclerosis. JAMA 1990;264:3013-7.
12. 12. Haskell W, Alderman E, Farin J, Maron D, Mackey S, Superko H, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Program (SCRIP). Circulation 1994;89:975-90.
13. 13. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
14. 14. Sacks E, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
15. 15. Shepherd J, Cobbe S, Ford I, Isles C, Lorimer A, MacFarlane P, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
16. 16. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
17. 17. Frohlich J, Fodor G, McPherson R, Genest J, Langner N. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Can J Cardiol 1998;14 (Suppl A):17A-21A.
18. 18. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92.
19. 19. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1997;17:2783-92.
20. 20. Kronenberg F, Kronenberg M, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck Study. Circulation 1999; 100:1154-60.
21. 21. Despres J. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect of patients' risk. Obes Res 1998;6:8S-17S.
22. 22. Kannel W. Effect of weight on cardiovascular disease. Am J Clin Nutr 1996; 63:419S-22S.
23. 23. US Department of Health and Human Services Centre for Disease Control and Prevention. Physical activity and health: a report of the Surgeon General. Atlanta: National Centre for Chronic Disease Prevention and Health Promotion; 1996.
24. 24. Pedersen T, Olsson A, Faergeman O, Kjekshus J, Wedel H, Berg K, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60.
25. 25. The Post Coronary Bypass Graft Trial Investigators. The effect of aggressive lowering of low density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary bypass grafts. N Engl J Med 1997;336:153-62.
26. 26. Pitt B, Water D, Brown V, van Boven A, Schwartz L, Title L, et al. Results of the Atorvastatin versus Revascularization Treatments (AVERT) study: an 18-month study of aggressive lipid-lowering in patient with stable coronary artery disease indicated for catheter-based revascularization (CR). N Engl J Med 1999;341:70-6.
27. 27. Second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel). JAMA 1993;269:3015-23.
28. 28. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment in patients with type 2 diabetes. Lancet 1998;353:837-53.
29. 29. Haffner S, Lehto S, Onnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
30. 30. Wilson P, D'Agostino R, Levy D, Belanger A, Silbershatz H, Kannel W. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-47.
31. 31. Grundy S. Hypertriglyceridemia, atherogenic dyslipidemia and metabolic syndrome. Am J Cardiol 1998;81:18B-25B.
32. 32. Canada's physical activity guide to health active living. Ottawa: Health Canada, Canadian Society for Exercise Physiology; 1998.
33. 33. Wood D, DeBacker G, Faergemann O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J 1998;19:1434-1503.
34. 34. Grundy S, Balady G, Criqui M, Fletcher G, Greenland P, Hiratzka L, et al. Guide to primary prevention of cardiovascular diseases: a statement for health care professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation 1997;95: 2329-31.
35. 35. Canada's food guide to healthy eating for people four years and over. Canada: Minister of Public Works and Government Services; 1997.
36. 36. Diet and cancer prevention: Official position of the Canadian Dietetic Association. J Can Diet Assoc 1997;48:144.
37. 37. La Rosa J, He J, Vupputuri S. Effects of status on the risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
38. 38. Castelli W, Garrison R, Wilson P, Abbott R, Kalousdian S, Kannel W. Incidence of coronary disease and lipoprotein cholesterol levels in the Framingham Heart Study. JAMA 1986;2256:2835-8.
39. 39. Assmann G, Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to the incidence of atherosclerotic coronary artery disease (the PROCAM Experience). Am J Cardiol 1992;70:733-7.